pLCKO Citations (15)

Originally described in: High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.
Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, Mis M, Zimmermann M, Fradet-Turcotte A, Sun S, Mero P, Dirks P, Sidhu S, Roth FP, Rissland OS, Durocher D, Angers S, Moffat J Cell. 2015 Dec 3;163(6):1515-26. doi: 10.1016/j.cell.2015.11.015. Epub 2015 Nov 25. PubMed Journal

---

Articles Citing pLCKO

Articles
Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors. Steinhart Z, Pavlovic Z, Chandrashekhar M, Hart T, Wang X, Zhang X, Robitaille M, Brown KR, Jaksani S, Overmeer R, Boj SF, Adams J, Pan J, Clevers H, Sidhu S, Moffat J, Angers S. Nat Med. 2017 Jan;23(1):60-68. doi: 10.1038/nm.4219. Epub 2016 Nov 21. PubMed
Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes. Neggers JE, Kwanten B, Dierckx T, Noguchi H, Voet A, Bral L, Minner K, Massant B, Kint N, Delforge M, Vercruysse T, Baloglu E, Senapedis W, Jacquemyn M, Daelemans D. Nat Commun. 2018 Feb 5;9(1):502. doi: 10.1038/s41467-017-02349-8. PubMed
Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response. Turowec JP, Lau EWT, Wang X, Brown KR, Fellouse FA, Jawanda KK, Pan J, Moffat J, Sidhu SS. J Biol Chem. 2019 Jan 25;294(4):1396-1409. doi: 10.1074/jbc.RA118.004420. Epub 2018 Dec 6. PubMed
The Mitochondrial Transacylase, Tafazzin, Regulates for AML Stemness by Modulating Intracellular Levels of Phospholipids. Seneviratne AK, Xu M, Henao JJA, Fajardo VA, Hao Z, Voisin V, Xu GW, Hurren R, Kim S, MacLean N, Wang X, Gronda M, Jeyaraju D, Jitkova Y, Ketela T, Mullokandov M, Sharon D, Thomas G, Chouinard-Watkins R, Hawley JR, Schafer C, Yau HL, Khuchua Z, Aman A, Al-Awar R, Gross A, Claypool SM, Bazinet RP, Lupien M, Chan S, De Carvalho DD, Minden MD, Bader GD, Stark KD, LeBlanc P, Schimmer AD. Cell Stem Cell. 2019 Apr 4;24(4):621-636.e16. doi: 10.1016/j.stem.2019.02.020. Epub 2019 Mar 28. PubMed
Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells. MacLeod G, Bozek DA, Rajakulendran N, Monteiro V, Ahmadi M, Steinhart Z, Kushida MM, Yu H, Coutinho FJ, Cavalli FMG, Restall I, Hao X, Hart T, Luchman HA, Weiss S, Dirks PB, Angers S. Cell Rep. 2019 Apr 16;27(3):971-986.e9. doi: 10.1016/j.celrep.2019.03.047. PubMed
Functional Enhancers Shape Extrachromosomal Oncogene Amplifications. Morton AR, Dogan-Artun N, Faber ZJ, MacLeod G, Bartels CF, Piazza MS, Allan KC, Mack SC, Wang X, Gimple RC, Wu Q, Rubin BP, Shetty S, Angers S, Dirks PB, Sallari RC, Lupien M, Rich JN, Scacheri PC. Cell. 2019 Nov 27;179(6):1330-1341.e13. doi: 10.1016/j.cell.2019.10.039. Epub 2019 Nov 21. PubMed
Genetic interaction mapping and exon-resolution functional genomics with a hybrid Cas9-Cas12a platform. Gonatopoulos-Pournatzis T, Aregger M, Brown KR, Farhangmehr S, Braunschweig U, Ward HN, Ha KCH, Weiss A, Billmann M, Durbic T, Myers CL, Blencowe BJ, Moffat J. Nat Biotechnol. 2020 May;38(5):638-648. doi: 10.1038/s41587-020-0437-z. Epub 2020 Mar 16. PubMed
enAsCas12a Enables CRISPR-Directed Evolution to Screen for Functional Drug Resistance Mutations in Sequences Inaccessible to SpCas9. Neggers JE, Jacquemyn M, Dierckx T, Kleinstiver BP, Thibaut HJ, Daelemans D. Mol Ther. 2021 Jan 6;29(1):208-224. doi: 10.1016/j.ymthe.2020.09.025. Epub 2020 Sep 20. PubMed
Multi-omics integration identifies a selective vulnerability of colorectal cancer subtypes to YM155. Zhan T, Faehling V, Rauscher B, Betge J, Ebert MP, Boutros M. Int J Cancer. 2021 Apr 15;148(8):1948-1963. doi: 10.1002/ijc.33393. Epub 2020 Dec 4. PubMed
Genome-scale CRISPR screening at high sensitivity with an empirically designed sgRNA library. Henkel L, Rauscher B, Schmitt B, Winter J, Boutros M. BMC Biol. 2020 Nov 23;18(1):174. doi: 10.1186/s12915-020-00905-1. PubMed
A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity. Barghout SH, Aman A, Nouri K, Blatman Z, Arevalo K, Thomas GE, MacLean N, Hurren R, Ketela T, Saini M, Abohawya M, Kiyota T, Al-Awar R, Schimmer AD. JCI Insight. 2021 Mar 8;6(5). pii: 141518. doi: 10.1172/jci.insight.141518. PubMed
Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. Baggen J, Persoons L, Vanstreels E, Jansen S, Van Looveren D, Boeckx B, Geudens V, De Man J, Jochmans D, Wauters J, Wauters E, Vanaudenaerde BM, Lambrechts D, Neyts J, Dallmeier K, Thibaut HJ, Jacquemyn M, Maes P, Daelemans D. Nat Genet. 2021 Apr;53(4):435-444. doi: 10.1038/s41588-021-00805-2. Epub 2021 Mar 8. PubMed
Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters. van Gils N, Verhagen HJMP, Broux M, Martianez T, Denkers F, Vermue E, Rutten A, Csikos T, Demeyer S, Cil M, Al M, Cools J, Janssen JJWM, Ossenkoppele GJ, Menezes RX, Smit L. iScience. 2022 Aug 25;25(9):105013. doi: 10.1016/j.isci.2022.105013. eCollection 2022 Sep 16. PubMed
TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry. Baggen J, Jacquemyn M, Persoons L, Vanstreels E, Pye VE, Wrobel AG, Calvaresi V, Martin SR, Roustan C, Cronin NB, Reading E, Thibaut HJ, Vercruysse T, Maes P, De Smet F, Yee A, Nivitchanyong T, Roell M, Franco-Hernandez N, Rhinn H, Mamchak AA, Ah Young-Chapon M, Brown E, Cherepanov P, Daelemans D. Cell. 2023 Aug 3;186(16):3427-3442.e22. doi: 10.1016/j.cell.2023.06.005. Epub 2023 Jul 7. PubMed
G6PD and ACSL3 are synthetic lethal partners of NF2 in Schwann cells. Kyrkou A, Valla R, Zhang Y, Ambrosi G, Laier S, Muller-Decker K, Boutros M, Teleman AA. Nat Commun. 2024 Jun 15;15(1):5115. doi: 10.1038/s41467-024-49298-7. PubMed

If you have published an article using this material, please email us at to have your article added to this page.